Terry Dunn, MD
Obstetrics & Gynecology · Denver, CONPI 1124042346
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (43.5%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Axonics, Inc. at 35.5% of the total. Reporting peaked in 2024 at $5,231 and has fallen 91.9% since, to $426 in 2025. Among obstetrics & gynecology clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 262 payments — averaging $55.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$5K
- Duchesnay USA Incorporated$4K
- Medtronic$3K
- Astellas Pharma US Inc$824
- Pfizer$374
- AbbVie$363
- plus $1K from 28 others
What the payments were for
- Consulting fees$8136%
- Speaking & faculty fees$3,50024%
- Travel & lodging$3,58524%
- Food & beverage$6,37844%
- Education$3843%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 40 | $5,201 |
| Duchesnay USA Incorporated | 7 | $3,566 |
| Medtronic(2 entities) | 48 | $2,887 |
| Astellas Pharma US Inc | 33 | $824 |
| Pfizer | 25 | $374 |
| AbbVie(2 entities) | 19 | $363 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 33 | $360 |
| Boston Scientific | 8 | $184 |
| Sumitomo Pharma America, Inc. | 5 | $110 |
| Therapeuticsmd, Inc. | 6 | $109 |
| Convatec Inc. | 3 | $86 |
| Eisai Inc. | 4 | $76 |
| Myovant Sciences Inc. | 3 | $54 |
| Merck | 3 | $48 |
| Ardelyx, Inc. | 1 | $34 |
| Vertical Pharmaceuticals, LLC | 2 | $33 |
| Baudax Bio Inc. | 2 | $33 |
| Caldera Medical, Inc | 2 | $32 |
| Exact Sciences | 1 | $29 |
| Currax Pharmaceuticals LLC | 2 | $26 |
| Sunovion Pharmaceuticals Inc. | 1 | $24 |
| Bayer | 1 | $22 |
| LSI Solutions Inc | 1 | $19 |
| Novo Nordisk | 1 | $18 |
| Circassia Inc. | 1 | $18 |
| Shire North American Group Inc | 1 | $17 |
| Ironwood Pharmaceuticals, Inc | 1 | $17 |
| Organon | 2 | $16 |
| Urovant Sciences Inc | 1 | $15 |
| AstraZeneca | 1 | $14 |
| Coloplast | 1 | $14 |
| Melinta Therapeutics, LLC | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $13 |
| Antares Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Axonics$4,083
- Osphena$3,500
- INTERSTIM$885
- Axonics r-SNM System$101
How this compares
$14,660 in reported general payments places this provider in the 95th percentile of 705 obstetrics & gynecology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 257 | $271,976 |
| PremarinEstrogens, Conjugated | 87 | $54,167 |
| GemtesaVibegron | 35 | $43,601 |
| Estradiol | 530 | $41,095 |
| Methenamine Hippurate | 285 | $19,199 |
| OsphenaOspemifene | 27 | $17,577 |
| MounjaroTirzepatide | 13 | $14,163 |
| EstringEstradiol | 22 | $11,438 |
| ImvexxyEstradiol | 23 | $8,312 |
| Hydroxyzine Hcl | 525 | $7,604 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 174 | $7,044 |
| MotegrityPrucalopride Succinate | 11 | $5,916 |
| Lubiprostone | 33 | $4,179 |
| YuvafemEstradiol | 31 | $3,924 |
| Solifenacin Succinate | 68 | $3,322 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $824 | $271,976257 claims |
| PfizerPremarin, Estring | $374 | $65,605109 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $110 | $43,60135 claims |
| Duchesnay USA IncorporatedOsphena | $3,566 | $17,57727 claims |
| Therapeuticsmd, Inc.Imvexxy | $109 | $8,31223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 705 obstetrics & gynecology providers in Colorado.
Other obstetrics & gynecology in Denver
- William BrownDenver$76K
- Kristina TocceDenver$57K
- Victor DabeleaDenver$18K
- Jeremiah BartleyDenver$15K
- Daniel JacobsonDenver$10K
- Bhavani ChillaraDenver$10K
- Natalia ArangoDenver$7K
- Lauren KauvarDenver$6K
- Sarah PayneDenver$6K
- John CraneLoveland$415K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.